Triple negative breast cancer has an extremely poor prognosis when chemotherapy is no longer effective. To overcome drug resistance, novel drug delivery systems based on nanoparticles have had remarkable success. We produced a novel nanoparticle component 'MDC' from milk-derived colloid. In order to evaluate the anti-cancer effect of MDC, we conducted in vitro and in vivo experiments on cancer cell lines and a primary tumor derived breast xenograft. Doxorubicin (Dox) conjugated to MDC (MDC-Dox) showed higher cancer cell growth inhibition than MDC alone especially in cell lines with high EGFR expression. In a mouse melanoma model, MDC-Dox significantly suppressed tumor growth when compared with free Dox.
4 doxorubicin (Dox) confined in liposomes that is sterically stabilized by grafting polyethylene glycol onto the surface [pegylated liposomal doxorubicine (PLD)]. PLD has a circulation half-life of 73.9 hours, whereas Dox has a short half-life of less than 10 min. This prolonged circulation facilitates 10-fold higher intracellular drug concentrations in metastatic sites of breast cancer compared with adjacent normal tissue 8 . Moreover, in a phase III trial of metastatic breast cancer in 2004, PLD reduced the myocardial damage to one-third of the free Dox due to its tumor-selective delivery. However, no survival benefit was obtained when compared with free Dox in the trial 9 . These results indicated that nanoparticles as a drug carrier had the potential for tumor selectivity, but not for intra-nuclear transition of Dox and increased therapeutic effect.
The use of milk proteins as drug delivery vehicles represents a new trend. Two milk proteins that have been already investigated for drug delivery applications are β-lactoglobulin and casein 10 . For instance, Bolisetty et al. generated amyloid fibrils from β-lactoglobulin, and found that their conjugation to metal nanoparticles enhanced cell permeability and toxicity
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. Haratifar et al. used tea catechin-casein complex to significantly decrease cancer cell proliferation 12 . However, these approaches were not subjected to in vivo experiments. We have developed an original nano-sized drug delivery system from milk derived colloid, which is called MDC. In this study, we evaluated its potential anti-cancer effects both in vitro and in vivo using a primary triple negative tumor derived xenograft.
Results

Characteristics of MDC
The parent molecule of MDC is a component of milk and the micelle size was 60-70nm in diameter (Figure 1a) . To elucidate how MDC changed its structure after penetrating into the cells and being taken into lysosomes, MDC micelles (Figure 1b , A) were exposed to low pH and oxidative environment for 20 hours.
As a result, an obvious change to the amyloidal structure (Figure 1b, B) was observed. In the next step, MDC marked with Fluorescein isothiocyanate (FITC) was locally injected into a single gland of the mammary glands of lactating mice. Twelve hours later, the animals were sacrificed and biopsies were taken for histological examination. A control microscopic image of the gland treated with PBS demonstrates a section of mammary gland with many intact alveoli that contain milk (Figure 1c ). In the contralateral gland treated with MDC, some of the alveoli were lumped or perforated (Figure 1d, A) . Their lumens were empty of milk and contained many shaded epithelial cells. A massive destruction of the secretory system was also found as a result of complete collapse of alveoli (Figure 1d , B) and was associated with intensive penetration of MDC into the cells of the alveolar wall (Figure 1d, C) . Equivalent level of destruction of the mice mammary gland was typically seen 3 to 7 days after the induction of post-lactational involution 13 . MDC uptake into cell culture was also examined using the HC11 mouse mammary epithelial cell line incubated with MDC marked with FITC. A confocal microscopic picture shows significant intracellular MDC visualized even after 30 minutes of incubation (Figure 1e, A) . Magnified images taken after 12 hours of incubation clearly demonstrated that the penetration of MDC into the cell was associated with distortion of its normal shape and formation of pseudo-tail (Figure 1e, B-D) . The penetration of MDC was not limited to a specific region of the cell. Thus, the results suggest that MDC conversion in the lysosome into a toxic substance may lead to lysosome perforation and release of enzymes into the cell cytoplasm, which is followed by cells death due to autolysis.
Anti-cancer effect of MDC for breast normal epithelium and cancer cell lines
In order to confirm the anti-cancer effect of MDC against breast cancer cell lines, we used an MTT assay in 2 breast epithelial cell lines (MCF-10A and MCF-12A) and 2 breast cancer cell lines (MDA-MB-231
and MDA-MB-468) using a variety of MDC concentrations (Figure 2a) . Treatments effects were most obvious at 72 hours post-treatment where cell proliferation rates of MDA-MB-468 was clearly decreased to approximately 40% compared with those of normal epithelial cell lines. However, other cell lines showed no clear inhibition effect. In the next step, we used MDC-Dox (Dox:100 uM) in these cell lines (Figure 2b) . The cell growth suppression was much greater than MDC alone and was almost completely inhibited at 72 hours in MDA-MB-468. As we confirmed that there was no free Dox in the MDC-Dox, the additional effect of this treatment on suppression of cell growth might be due to the increase of cell toxicity by the Dox conjugation to MDC, or in other words, MDC served as a carrier that introduced Dox into the cell interior. However, the effect of MDC-Dox was also seen in normal cell lines. Also, inhibition rate was widely different between the two cancer cell lines: which indicated that membrane permeability was different. Although both cell lines are triple-negative breast cancers, the expression of epidermal growth factor receptor (EGFR) in MDA-MB-231 is (1+) and that of MDA-MB-468 is (3+) according to a previous paper 14 . In order to further explore the association between MDC effect and EGFR expression, we tested the effect of MDC on another two cell lines, Figure 2 ) which have moderate EGFR expressions (2+). Thus, our results suggest that MDC contains cluster motifs on its surface that can bind to EGFR, or to molecules closely associated to EGFR, and the anti-cell proliferation ability of MDC seems to be more pronounced in higher EGFR-bearing cells.
Comparison of Dox conjugated MDC with free Dox in vitro setting
MDC-Dox was also compared with free Dox in in vitro experiments. Based on EGFR expression, we used the MDA-MB-453 breast cancer cell line (EGFR zero) [14] , MDA-MB-468 breast cancer cell line (EGFR 3+) and A-431 epidermoid carcinoma cell line (EGFR strongly positive) 15 for the MTT assay (Supplementary Figure S2) . Consistent with the above-described experiments, MDC-Dox effects on cell proliferation were more pronounced in higher EGFR-expressing cell lines (Supplementary Figure S2 b ).
However, MDC-Dox effects and Dox effects on cell proliferation were almost similar, suggesting that Dox can easily penetrate into cells by its hydrophobic nature when Dox directly contacts cells. The equal effects of MDC-Dox and Dox are consistent with the iso-concentration of Dox in the two preparations, and suggest that the phagocytic uptake of MDC-Dox into cells is not inferior to penetration into cells by diffusion of Dox.
Optimal Dox concentration for the conjugation to MDC
We tried to increase the concentration of Dox (100 uM, 300 uM, 350 uM and 900 uM) conjugated to a constant amount of MDC. The inhibition rates of cell proliferations in MDC-Dox were always superior to MDC alone in various Dox concentrations except for 900 uM (data not shown). However, 900uM of Dox conjugation to MDC failed neither to overcome MDC alone nor to show any tumor growth inhibition. These observations suggest that too much Dox conjugation modified the three-dimensional structure of MDC and prevented it from binding it's ligand to the cell membrane while it still held most of the Dox tightly and thus prevented the toxic effect of free Dox.
In vivo experiments using a mice melanoma xenograft model
In order to examine whether MDC-Dox has advantage superior anti-cancer effect over free Dox under in vivo conditions, we conducted mice experiments. Initially, we applied our drug to B16-F0-luc mice melanoma model on C57BL/6NCR black mice because of the convenience of the homologous tumor. Also, the B16 cell line has good EGFR expression (Supplementary Figure S3 ) 16 and showed favorable sensitivity to MDC-Dox in vitro experiment (data not shown). Average tumor volume change of each group (control: PBS, free Dox and MDC-Dox, n=10 respectively) is shown in Figure 3a . The dosage of Dox in free Dox and MDC-Dox was 2.5 mg/kg/week, which was just the half of maximal dose for mice. The mice treated with MDC-Dox clearly showed significant tumor growth suppression when compared with free Dox, after day 17.
Moreover, tumors in the free Dox group displayed continued growth and larger volumes than control at the end of the experiment. Less tumor growth in the MDC-Dox group was clearly seen in the IVIS images taken on day 21 (Figure 3b ) and tumor images taken on day23 (Figure 3c ). Mice body weight in the MDC-Dox group was significantly lower than Dox alone at the beginning of the experiment; however, no difference in body weight was found later. At the end, Dox alone group showed increased body weight due to larger tumor volume (Figure 3d) . As a result, mice in the MDC-Dox group had relatively better overall survival than control (P=0.105, log-rank test) and free Dox (P=0.095, log-rank test) (Figure 3e) . All of mice died of cancer and many of them were euthanized because of oversized tumors. No visible distant metastasis was found at autopsy.
FITC labeled MDC-Dox was injected intravenously into another mouse and euthanized 24 hours later. Tumor tissues and several organs were collected from the mice and observed by fluorescence microscope. As we expected, fluorescence signals were detected in the tumor (Figure 4a ), but not in the heart tissue ( Figure 4b ) and in the liver tissue (Figure 4c ). In addition, necrotic cells were abundant around the fluorescence detected area in the tumor (Figure 4a) . These pictures clearly demonstrate that MDC-Dox was selectively delivered to the tumor.
Lymphocyte phenotyping analysis was performed using locoregional lymph nodes and a spleen of Table S1 ). Also, antigen specific T cell activations occurred in tumor lysate of MDC-Dox group (7.15) just like in that of Dox group (8.47) (Supplementary Table S2 ).
In vivo experiment using immunodeficient mice with a primary human breast cancer tumorgraft
As the advantage and tumor selectivity of MDC-Dox was demonstrated in the mice melanoma model, we proceeded to apply this reagent to a primary tumor derived human breast cancer model. We Table S3) did not differ between the treatments.
Discussion
The recent success of nanoparticles as drug carriers has changed the practice of oncology for some tumor types. One advantage of these drugs may come from their ability to bypass multi-drug resistance (MDR). One of the main mechanisms for drug resistance is activation of efflux pumps that eliminate the drugs from the cells and indeed, P-glycoprotein (Pgp) is known as a major cause of chemotherapy failure.
Over expression of Pgp on the cell membrane can actively efflux various anticancer drugs from the cell, and reduce the intracellular drug dose 17 . Since the efflux channel of Pgp is limited to small substrates (300-2000Da) 18 , nanoparticles (over 10000Da) can avoid efflux and stay inside the cell thus overcoming MDR at least in theory.
Other mechanisms of resistance to chemotherapy include amplification of genes that help cancer cells to cope with drugs 19 or increase in DNA repair after damage from chemotherapeutic agents 20 . In our case, drug is delivered to the lysosomes by MDC where it induces lysosomal-mediated cell death due to release of enzymes stored in the lysosome. Thus, this type of cell death should also be effective in drug resistant cancer cells with genomic alterations, as the released enzymes will destroy the whole cell interior.
Interestingly, lysosomal-mediated cell death is considered as the main mechanism of the massive cells loss that associate with mammary gland involution 21 . Thus, MDC might have a natural role in inducing involution of mammary glands.
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The size of the nanoparticle determines its efficiency as a drug carrier. In previous studies, it was found that particles in the range of 60-400nm extravasate and accumulate in tumors via a passive mechanism, called 'enhanced permeability and retention (EPR)' effect 22 . Accordingly, the size of MDC (60-70 nm) or Doxil (80-90 nm 7 ) are in the suitable range for inducing the EPR effect. However, only particles in the range of 30 nm in diameter could penetrate into poorly permeable pancreatic tumors 23 . Also, only small molecules (9-40 nm in diameter) can pass through the nuclear envelop if they are to function inside the nucleus envelop 24, 25 .
One of the critical characteristics of nanoparticles as a drug delivery system is the ability to lower dose administration and thus toxcicity. This notion is supported by data showing a long resident time in the blood and high tumor-specific delivery for some nanaoparticles. Lu et al examined the pharmacodynamics of pegylated lipopsomal doxorubicine (PL-Dox) and free Dox. The half-life of injected 5mg/kg Dox in mice was twice longer in PL-Dox than free Dox. Moreover, the Dox concentration in stomach, small intestine and heart tissues were significantly reduced. Moreover, the difference in tumor growth inhibition was larger during the administration of a low drug concentration than that of a high concentration 26 . . Similarly, in the melanoma model in this study, although just half (2.5mg/kg) 13 of the maximal Dox dosage (5mg/kg) was administrated to mice, the MDC-Dox conjugated group still showed significant tumor growth inhibition when compared with the free Dox group. Furthermore, the lack of evidence of penetration of MDC-Dox into heart and liver indicates that anti-tumor effects were induced with likely minimal side effects to essential organs.
Another advantage of nanoparticles may be their vessel protection effect in the circulating blood. Our experiments only demonstrated part of the potential broad spectrum applications of MDC. As almost all anti-cancer drugs are highly hydrophobic, MDC can theoretically bind to any existing drug effectively. Actually, we have already verified the capacity of MDC to bind strongly and efficiently to curcumin, daunorubicin and methotrexate. Moreover, as MDC is a protein and capable to undergo ionic covalent interactions, it will be quite easy to develop MDC as a carrier of micro RNA, shRNA and ligands or antibodies of plasma membrane receptors. Thus, MDC might be applied as a universal tumor-specific drug carrier.
In conclusion, we demonstrated that a novel nanoparticle made of milk-derived colloid has an anti-cancer effect and tumor-specific accumulation. The tumor-specific accumulation property of MDC is associated with its particle size and tendency to interact with EGFR which is amplified in many cancer cell 
Materials and methods
Preparation of Dox conjugated MDC micelles
A colloid made of protein was isolated from milk, which we defined here as MDC. As MDC has the propensity to bind strongly hydrophobic substances, Dox can be firmly bound to MDC by hydrophobic interactions. To determine the binding kinetics of Dox from Dox conjugated MDC (MDC-Dox), 0.5 mL of MDC-Dox solution was placed in a dialysis bag (molecular weight cut-off, 10 kDa) which was incubated in 30 mL of phosphate-buffered solution (pH 7.4) containing Tween 80 (0.5% w/w) at 37°C with gentle shaking for 72 h. Although the Dox molecular weight was much lower than the molecular weight cut-off, there was no leak of Dox from the bag.
Cell culture
HC11 mouse mammary epithelial cells were cultured at 5% CO 2 in DMEM/F12 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 10 ng/ml of EGF (Invitrogen), 5 μg/ml of insulin (Sigma-Aldrich, St. Louis, MO), and 1 μg/ml hydrocortisone (Sigma-Aldrich). As for human breast cancer cell lines, MCF-10A cells were cultured with MEGM kit with 100ng/ml of cholera toxin (Sigma-Aldrich) and without GA-1000 (gentamycin-amphotericin B mix). MCF-12A was cultured with DMEM/F12 with 20 ng/ml of EGF, 100ng/ml of cholera toxin, 10ug/ml of bovine insulin, 500ng/ml of hydrocortisone and 5% horse serum. MCF-7, MDA-MB-468, MDA-MB-231, and A-431 was cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin solution. BT-474 cells were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin solution.
MDA-MB-453 cells were cultured in RPMI medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin solution. All cell lines described above were purchased from American Type Culture Collection (Manassas, VA). The B16-F0-luc mice melanoma cell line was purchased from JCRB cell bank (Osaka, Japan) and cultured in DMEM medium supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin solution. All of these cell lines were maintained in a humidified chamber at 37°C in an atmosphere containing 5% CO 2 .
Cell proliferation assay (MTT assay)
The sensitivities to MDC of various breast cancer cell lines were compared by a cell proliferation Briefly, 10 μl of MTT labeling reagent (5 mg/ml MTT) was added to the culture medium, which was then incubated in the dark for a further 4 h at 37°C. This step was followed by cell lysis with the addition of 100 μl of a detergent reagent. The plates were incubated for 2 h at 37°C to dissolve formazan crystals.
Spectrophotometric readings (570nm/650nm) were obtained on a Spectra Max 250 96-well plate reader (Molecular Devices). Each assay was performed in triplicate, and each experiment was repeated at least three times.
In vivo experiment using mice melanoma tumorgraft on C57BL/6NCR black mice
Mice melanoma cancer B16-F0-luc cells ( To record the survival of the tumor-bearing mice, either natural death or a tumor diameter greater than 2 cm leading to death was considered death. Tumor viability was also measured by intra-peritoneal injection of 50ug/g luciferine using an In Vivo Imaging System (IVIS) (PerkinElmer, Waltham, MA). 
Tissue phenotyping
Breast cancer tumor grafts model on immunodeficient mice
Experiments in vivo of the breast cancer tumor graft were performed at Champions Oncology 
Statistical analysis
Continuous values were compared by student's t-tests two tailed. Mouse survival in each group was compared by Kaplan-Meier curves and log-rank test. P value of <0.05 was considered statistically significant.
All statistical analyses were performed using JMP 9 software (SAS institute, Cary, USA). (Figure 1d, A) . Their lumens were empty of milk and contained abundant shaded epithelial cells. A massive destruction of the secretory system was also found as a result of complete collapse of alveoli (Figure 1d, B) and was associated with intensive penetration of MDC into the cells of the alveolar wall (Figure 1d, C) .e:
HC11 mice mammary epithelial cells were incubated with MDC conjugated with FITC. Confocal microscopy showed significant intracellular MDC visualized only even after 30 minutes of incubation (Figure 1e, A) .
Magnified images taken after 12 hours of incubation clearly demonstrated that the penetration of MDC into the cell was associated with distortion of its normal shape and formation of a pseudo-tail (Figure 1e, B-D) . 
Supplementary Figure S3
Western blotting analysis of EGFR protein was performed. Primary and secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA). EGFR expression of breast cancer tumor graft and B16-F0-luc were examined. A453 cell line was used as an EGFR negative control. ACTB was used as a reference (Sigma-Aldrich). Drug dilution
Supplementary Figure S4
